Physician profile
Mark R Vandien
NPI 1194951905
$1,411.91
in general payments reported to CMS, 2019-2025
17 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $57.34 · 2023: $281 · 2024: $531 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $308.81 | 2023-2025 | |
| Abbott Laboratories | $198.25 | 2022-2025 | Cardiomems, Gallant, Jot Dx |
| Baxter Healthcare | $184.63 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $111.93 | 2023-2025 | |
| Scpharmaceuticals INC. | $101.97 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.62 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $78.82 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.78 | 2025 | Jardiance |
| Amgen INC. | $57.90 | 2023-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $47.34 | 2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $42.87 | 2024 | |
| Cvrx, INC. | $33.00 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $21.94 | 2025 | Opsumit |
| Kiniksa Pharmaceuticals, LTD. | $19.55 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $16.32 | 2025 | Attruby |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $13.70 | 2024 | Bodyguardian |
| Janssen Pharmaceuticals, INC | $13.48 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vandien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.